TOPIC

Biomedicine: Companies

Related Topics:
Biomedicine: Companies
Learn about China’s biomedical breakthroughs, from cutting-edge pharmaceuticals to life-saving research, driving global health innovation.
Chinese biotech firms set to crack the global market within a decade, according to industry experts. Photo: Getty Images
China manufacturing

China’s biotech firms may see ‘major breakthroughs’ within a decade. Here’s why

Strong manufacturing base a driving force behind overseas expansion, but industry leaders and analysts say hurdles remain.

videocam
Made in China 2025

China’s Fosun Pharma unit strikes US$2.1 billion obesity drug deal with Pfizer

China economy

Opinion | How China engineered the rapid rise of its drug innovation industry

videocam
Hong Kong stock market

China’s 3SBio seeks US$400 million in Hong Kong to boost drug pipeline

Share placement to help Shenyang-based firm advance clinical research in China and the US, expand reach of cancer and hair-loss drugs.

Shenyang-based 3SBio is selling a 4.14 per cent stake in the company. Photo: Handout
Biomedicine: Industry Trends

China’s clinical trial capacity matches US, attracts more global pharma firms

Growth of innovative clinical trials suggests that Chinese biotech firms’ pipeline of novel drug candidates is expanding, analysts say.

New medical drugs

6 of the best: the billion-dollar biotechs putting China on the map

China’s biotech renaissance is gathering pace as home-grown innovators strike billion-dollar licensing deals with global giants.

Advertisement
Advertisement
Advertisement
Hong Kong healthcare and hospitals

Hong Kong biotech firm to back controversial sanitary pad HPV test with evidence

Dr Choi Pui-wah, founder of WomenX Biotech, also says she remains optimistic about Hong Kong as a tech destination despite government warning.

Dr Choi Pui-wah, founder of WomenX Biotech, also says she remains optimistic about Hong Kong as a tech destination. Photo: K. Y. Cheng
Biomedicine: Industry Trends

China biotech forum bills antibody cancer drugs as next-generation treatment

Biotech insiders tout antibody-drug conjugates as the next big thing in cancer treatment, with firms urged to pursue global strategies.

Greater Bay Area

BeOne Medicines to expand cancer-drug offerings in Hong Kong

Fresh off a profitable half year, a global drug company that started as an R&D firm in Beijing plans to expand production in Guangzhou.

Hong Kong stock market

China’s Akeso gets share boost as data shows cancer drug’s benefits

Lung-cancer drug ivonescimab is ‘potentially two to three years ahead of competitors’, analyst says.

Trial showed “a decisive and strong positive outcome with both significant and clinically meaningful benefits”, Akeso said. Photo: Shutterstock
Biomedicine: Science

Hansoh and Leads Biolabs clinch US$2.5 billion in global drug licensing deals

Two mainland biotech firms win global attention as Roche and Dianthus sign major licensing pacts, highlighting China’s growing role in next-generation drug development.

China’s Hansoh and Leads Biolabs clinch US$2.5 billion in global drug licensing deals
HKEX

HKEX’s new Hang Seng Biotech Index Futures to debut next month

The futures contracts platform aims to meet offshore investors’ heightened interest in Hong Kong-listed Chinese biopharmaceutical stocks.

Start-ups

Singapore’s Nanyang Biologics to list on Nasdaq amid Trump’s pharma tariffs

The start-up agrees to merge with a special-purpose acquisition company in a deal that puts its value at US$1.5 billion.

Greater Bay Area

Hong Kong MRI maker Time Medical seeks site to boost output, eyes IPO

Aiming to grow sales to US$300 million in 2027, the company is eyeing a Nasdaq IPO and then a Hong Kong secondary listing.

Ma Qiyuan, Time Medical Systems co-founder and chairman, pictured with one of the company’s scanners in its facility in Tai Po on October 6, 2025. Photo: Jonathan Wong
China-Africa relations

China’s ‘health silk road’ in Africa gets a boost with insulin, pharma projects

Move to manufacture insulin locally is set against forecast of nearly 55 million Type 2 diabetes cases in sub-Saharan Africa by 2045.

videocam
Nigeria is expected to produce insulin and HIV drugs in partnership with Chinese firms, while the Ivory Coast will similarly make antimalarial drugs and antibiotics. Photo: Shutterstock
Biomedicine: Science

Mirxes wins China’s approval to launch groundbreaking gastric cancer blood test

The non-invasive blood test helps in the early detection of the fifth leading cause of cancer deaths globally.

IPO

Exclusive | Hong Kong ‘critical’ as investors ‘rediscover’ China: Morgan Stanley

City’s capital market lets innovative Chinese companies ‘position longer-term value propositions to the global investor base’, banker says.

Advertisement
Advertisement
Advertisement
Health & Fitness

Li Ka-shing-backed focused ultrasound therapy treats 1 millionth case

The therapy, which uses ultrasound energy to treat a number of diseases including cancer, is gaining global traction, a US expert says.

Minnesota-based HistoSonics makes focused ultrasound machines for treating liver tumours. Photo: Handout
United States

China’s pharmaceutical sector surges amid growth in sales, licensing income

Strong growth momentum and global push expected to continue, HSBC says.

IPO

Chinese healthcare, biotech firms flock to Hong Kong for IPOs

September yields at least 23 listing applications from mainland biotech firms eyeing the city’s lucrative fundraising market.

Baidu

Baidu-backed drug discovery start-up Biomap challenges Google’s AlphaFold

Biomap expects to double its revenue this year, co-founder and CEO Wei Liu says.

From left to right: HKIC CEO Clara Chan Ka-chai, Financial Secretary Paul Chan Mo-po and Biomap CEO Wei Liu at a signing ceremony in June. Photo: Handout
Biomedicine: Geopolitics

Trump’s tariffs on imported drugs ‘not a big concern’ for China’s pharma firms

Chinese drug makers have ‘minimal sales exposure to the US’, Jefferies analysts say.

The Trump administration’s new 100 per cent tariff on any branded or patented pharmaceutical product takes effect on October 1. Photo: Shutterstock
Biomedicine: Industry Trends

Pfizer’s Metsera acquisition to spur Chinese search for new weight drugs

The deal, worth up to US$7.3 billion, will encourage ongoing investment by mainland players but not draw in new rivals, analysts say.

Jiangsu Hengrui Pharmaceuticals

China’s Hengrui gets boost from fifth drug-licensing deal of year

Shares rise after Mumbai-based Glenmark Pharmaceuticals strikes deal for cancer drug.

US-China relations

Opinion | Why US-China health and drugs cooperation must top Trump-Xi agenda

The years-long impasse harms both nations and the world, and the stakes in global health security could not be higher.

videocam
Illustration: Craig Stephens
Health in China

Beijing tackles drug price wars with new tendering rules in anti-involution push

China’s new drug procurement rules prioritise quality over price in a bid to curb cutthroat competition.

Employees work on the production line of Shijiazhuang No 4 Pharmaceutical in Shijiazhuang, Hebei province. Photo: VCG/VCG via Getty Images
Biomedicine: Industry Trends

Ascletis trial shows drug candidate ASC47 boosts semaglutide weight loss effect

Chinese biotech firm is among dozens of mainland drug makers seeking to compete in the global market for diabetes and weight-loss drugs.

Hong Kong stock market

Chinese biotechs get a shot in the arm from policy support, licensing deals

‘We are on an upcycle in the industry and sentiment is very strong,’ Xufunds Investment fund manager Wang Chen says.

Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement